Insulet Corporation $PODD Position Lifted by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky boosted its position in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 444.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 173,737 shares of the medical instruments supplier’s stock after purchasing an additional 141,849 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.25% of Insulet worth $22,668,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. West Family Investments Inc. raised its holdings in Insulet by 29.9% in the third quarter. West Family Investments Inc. now owns 2,792 shares of the medical instruments supplier’s stock worth $364,000 after purchasing an additional 643 shares during the period. Hantz Financial Services Inc. boosted its position in shares of Insulet by 29.1% during the third quarter. Hantz Financial Services Inc. now owns 1,803 shares of the medical instruments supplier’s stock worth $235,000 after purchasing an additional 406 shares in the last quarter. Diversified Trust Co boosted its position in shares of Insulet by 47.0% during the third quarter. Diversified Trust Co now owns 5,036 shares of the medical instruments supplier’s stock worth $657,000 after purchasing an additional 1,611 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Insulet by 2.3% in the 3rd quarter. Allworth Financial LP now owns 3,104 shares of the medical instruments supplier’s stock valued at $405,000 after buying an additional 71 shares during the period. Finally, Fifth Third Bancorp grew its holdings in shares of Insulet by 21.3% in the 3rd quarter. Fifth Third Bancorp now owns 64,540 shares of the medical instruments supplier’s stock valued at $8,421,000 after buying an additional 11,334 shares during the period.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Royal Bank Of Canada raised their price objective on Insulet from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Leerink Partners lifted their target price on Insulet from $143.00 to $167.00 and gave the stock a “market perform” rating in a report on Thursday, November 5th. JPMorgan Chase & Co. boosted their target price on Insulet from $152.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday, November 5th. Finally, Oppenheimer downgraded Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Twelve analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $185.67.

Get Our Latest Stock Report on Insulet

Insulet Stock Performance

Shares of PODD opened at $145.34 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The firm’s 50 day moving average price is $142.16 and its two-hundred day moving average price is $172.43. The firm has a market cap of $10.08 billion, a P/E ratio of 23.67, a PEG ratio of 1.11 and a beta of 1.06.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The company had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. During the same quarter in the prior year, the company earned $1.24 earnings per share. The business’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, analysts forecast that Insulet Corporation will post 6.76 EPS for the current fiscal year.

Insulet Company Profile

(Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Further Reading

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.